Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model

Neoplasia

Volumn 13, Issue 1, 2011, Pages 23-30

  Zhang, Jian ^a   Sud, Sudha ^a   Mizutani, Kosuke ^a   Gyetko, Margaret R ^b   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CELL INFILTRATION; CONTROLLED STUDY; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 78650996236     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10728     Document Type: Article

References (37)

1. Smith HW and Marshall CJ (2010). Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11, 23-36.
2. Li Y and Cozzi PJ (2007). Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 33, 521-527.
3. Duffy MJ (1990). Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1, 681-687.
4. Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, and Dano K (1988). Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 111, 42-51.
5. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, and Sumiyoshi A (1992). The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50, 871-873.
6. Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, and Takada A (1988). The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res 50, 527-535.
7. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, and Kamidono S (1999). Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39, 123-129.
8. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, and Slawin KM (2007). Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25, 349-355.
9. Lilja H, Vickers A, and Scardino P (2007). Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. J Clin Oncol 25, 347-348.
10. Miyake H, Hara I, Yamanaka K, Arakawa S, and Kamidono S (1999). Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14, 535-541.
11. Van Veldhuizen PJ, Sadasivan R, Cherian R, and Wyatt A (1996). Urokinasetype plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312, 8-11.
12. Gavrilov D, Kenzior O, Evans M, Calaluce R, and Folk WR (2001). Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 37, 1033-1040.
13. Usher PA, Thomsen OF, Iversen P, Johnsen M, Brunner N, Hoyer-Hansen G, Andreasen P, Dano K, and Nielsen BS (2005). Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 113, 870-880.
14. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, and Li Y (2006). Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37, 1442-1451.
15. Pulukuri SM, Estes N, Patel J, and Rao JS (2007). Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res 67, 930-939.
16. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, and Rao JS (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280, 36529-36540.
17. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, and Cher ML (2008). Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 10, 439-449.
18. Gyetko MR, Todd RF III, Wilkinson CC, and Sitrin RG (1994). The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93, 1380-1387.
19. Bryer SC, Fantuzzi G, Van Rooijen N, and Koh TJ (2008). Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J Immunol 180, 1179-1188.
20. Sica A, Schioppa T, Mantovani A, and Allavena P (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42, 717-727.
21. Balkwill F and Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357, 539-545.
22. Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420, 860-867.
23. Solinas G, Germano G, Mantovani A, and Allavena P (2009). Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86, 1065-1073.
24. Kubo H, Morgenstern D, Quinian WM, Ward PA, Dinauer MC, and Doerschuk CM (1996). Preservation of complement-induced lung injury in mice with deficiency of NADPH oxidase. J Clin Invest 97, 2680-2684.
25. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, and Mulligan RC (1994). Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424.
26. Dewerchin M, Nuffelen AV, Wallays G, Bouche A, Moons L, Carmeliet P, Mulligan RC, and Collen D (1996). Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 97, 870-878.
27. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, and Toews GB (1996). Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 97, 1818-1826.
28. Thompson TC, Southgate J, Kitchener G, and Land H (1989). Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56, 917-930.
29. Baley PA, Yoshida K, Qian W, Sehgal I, and Thompson TC (1995). Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52, 403-413.
30. Lu Y, Nie D, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, and Zhang J (2008). Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 ß phosphorylation. Mol Cancer Ther 7, 3203-3211.
31. Kindzelskii AL, Amhad I, Keller D, Zhou MJ, Haugland RP, Garni-Wagner BA, Gyetko MR, Todd RF III, and Petty HR (2004). Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinasetype plasminogen activator. Histochem Cell Biol 121, 299-310.
32. Power CA, Pwint H, Chan J, Cho J, Yu Y, Walsh W, and Russell PJ (2009). A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate 69, 1613-1623.
33. Austyn JM and Gordon S (1981). F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11, 805-815.
34. Mekkawy AH, Morris DL, and Pourgholami MH (2009). Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 5, 1487-1499.
35. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, and Castellino FJ (2000). Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60, 5839-5847.
36. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, and Mukhtar H (2009). Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 15, 452-459.
37. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, and Sarkar FH (2010). Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-κB signaling pathways. J Cell Biochem 109, 726-736.